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1. Introduction 
Gene therapy involves the transfer of genetic material into cells of an individual to treat an 
underlying illness either through the expression of advantageous genes or the silencing of 
disadvantageous ones (Flotte 2007; Kohn and Candotti 2009). Gene therapy has been used 
successfully to treat several diseases, for example SCID-X1 (Cavazzana-Calvo, Hacein-Bey et 
al. 2000) and SCID-ADA (Aiuti 2004) and holds out promise as a more general treatment 
regimen (Flotte 2007). One of the driving forces behind the area of research into the treatment 
of HIV is the resistance to, and side effects of, the current drugs being used. This development 
of resistance and the need for continuous and ongoing daily medication have been major 
shortcomings of conventional highly active antiretroviral therapy (HAART) when employed 
as a treatment against HIV (Perno, Moyle et al. 2008). An additional driving force behind 
interest in gene therapy is the potential for a one-off treatment that would continue to work for 
the life of the individual (Symonds, Johnstone et al. 2010). One can envisage gene therapy as a 
full or partial replacement for HAART, that may help to overcome issues of viral resistance, 
co-morbidity and attendant compliance (i.e. daily administration of HAART for life). 
While HAART is a systemic form of treatment which provides a substantial level of 
protection to HIV susceptible cells in the body for many years, it is highly susceptible to the 
development of a resistant HIV quasispecies, that may selectively expand due to the strong 
evolutionary pressure exerted by HAART (Perno, Moyle et al. 2008). Whereas HAART-
based treatments bathe each cell in some level of drug, gene-therapy results in a polar 
population dynamic consisting of gene protected and unprotected cells. This is due to the 
fact that it is neither practical nor possible to have a protective gene against HIV introduced 
into all cells of the body, but rather only a subset of the total cell population is afforded 
protection (Symonds, Johnstone et al. 2010). This polar dynamic is predicted to provide 
additional pressures to the suriviving HIV population (Applegate, Birkett et al. 2010). Cells 
that might be afforded protection include CD4+ T cells and macrophages, which are known 
to be targets of HIV infection, as well as other cell populations susceptible to HIV infection.  
In this chapter we describe the biological and clinical underpinnings of gene-therapy 
including the therapeutic genes employed for protection against HIV, delivery methods of 
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the vectors carrying these protective genes into the cells, expression cassettes and finally the 
target cells into which the protective genes are introduced. We then estimate the potential 
in-vivo protective effects of gene-therapy against HIV. 
2. Biological and clinical aspects of gene-therapy 
In this section we look at the biological and clinical aspects of gene-therapy. Observations 
associated with natural immunity that may be utilized in gene-therapy against HIV are 
discussed in section 2.1. Stages of the HIV infection cycle that may be inhibited by gene-
therapy, and the various gene therapeutic that may be employed to this aim, are the subject 
of section 2.2. Various delivery vectors and promoters that can achieve effective delivery 
and transcription of the protective gene into the cell to be transduced are the subject of 
section 2.3. The biological underpinnings of the target cell to be transduced with a protective 
gene, either CD4+ T cells or Hematopoietic Stem Cells (HSC) are discussed in section 2.4. 
The clinical aspects of collection of cells for transduction via apheresis and associated 
preparation regimens are discussed in section 2.5. Finally, Section 2.6 is concerned with 
clinical trials to-date of anti-HIV gene-therapy and results reported therein. 
2.1 CCR5 and the 32-nucleotide deletion mutation: A strong case for gene therapy 
Recent additional impetus for gene-therapy for HIV is based upon the earlier observation 
that some individuals do not become infected upon repeated exposure to HIV 
(Zimmerman, Buckler-White et al. 1997). Studies of these individuals led to the discovery 
of a mutation in CCR5, an important co-receptor for HIV attachment to target cells prior 
to infection. Such a mutation was found to confer natural immunity against HIV 
(Zimmerman, Buckler-White et al. 1997). 
The mutation discovered was found to be a 32 nucleotide deletion (CCR5d32) within the 
CCR5 gene (Zimmerman, Buckler-White et al. 1997). This mutation was observed to be very 
common among individuals of European background and it has subsequently been 
determined that of Caucasian individuals, approximately 10% are heterozygous and 1-3% 
homozygous for this mutation (Dean, Carrington et al. 1996; Liu, Paxton et al. 1996; Samson, 
Libert et al. 1996; Agrawal, Lu et al. 2004), with the mutation being almost non-existent in all 
other populations. There has been considerable speculation regarding the origin and 
purpose of the mutation. It has been shown that the percentage of CCR5d32 mutation 
occurring in today’s population is roughly comparable to that found in samples from 
individuals of the Bronze Age (approximately 3000 years ago) (Hummel, Schmidt et al. 2005; 
Hedrick and Verrelli 2006). There is evidence suggesting that smallpox provided a selective 
advantage for CCR5d32 (Galvani and Slatkin 2003), indicating that there may be other 
selective advantages associated with the mutation. The mutation does not seem to present 
any significant disadvantages to the individuals other than an increased risk of West-Nile 
disease (Glass, McDermott et al. 2006). Such observations led to an interest in mimicking this 
natural mutation for HIV-infected individuals via genetic manipulation (i.e. transduction) of 
cells vulnerable to HIV infection. (see below) 
It has been noted that the 32 nucleotide deletion results in 31 new amino acids being coded 
for, resulting in an active CCR5d32 protein. This protein instead of presenting as CCR5 
receptors on the cell surface like the wild-type counterpart, CCR5d32 actually binds to and 
interacts with CXCR4 receptors (Agrawal, Lu et al. 2004), the other major coreceptor for HIV 
attachment. This provides an additional protection against HIV infection beyond the mere 
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absence of a functional CCR5 co-receptor, especially when concerning strains capable of 
utilizing the CXCR4 coreceptor (Agrawal, Lu et al. 2004; Jin, Agrawal et al. 2008). Further 
evidence towards the beneficial effect of the CCR5d32 protein comes from evidence that a 
polymorphism in the promoter region in CCR5-/- individuals can affect the protective 
capabilities of the d32 mutation. It has been demonstrated that an increase in CCR5d32 
protein expression will improve resistance to HIV, while decreased CCR5d32 expression 
reduces the protective effect (Jin, Agrawal et al. 2008). 
This CCR5d32 mutation has been successfully utilized in a patient, who suffered from both 
HIV/AIDS and leukaemia (Hutter, Nowak et al. 2009; Allers, Hutter et al. 2010). This 
individual, termed the “Berlin patient”, had complete ablation of their immune system (to 
treat the leukemia) before matched allogeneic donor hematopoietic stem cells (HSC) 
homozygous for the CCR5d32 mutation were transfused into the patient. After one 
recurrence of leukaemia and a repeat of the treatment (ablation and reconstitution), the 
patient has had undetectable levels of HIV (and no recurring leukaemia) for more than 3 
years without the use of any antiretroviral drugs (Hutter, Nowak et al. 2009; Allers, Hutter 
et al. 2010). This unique result of “functional” cure of HIV indicates significant potential for 
the use of gene-therapy to mimic this result by down-regulation of CCR5. 
2.2 Choosing a stage of HIV infection cycle to inhibit: Which therapeutic genes hold 
out promise? 
2.2.1 Classes and methods of HIV inhibition  
Gene-therapy may be aimed to target various stages of the HIV infection cycle as shown in 
Figure 1. Class 1 therapy inhibits all steps prior to viral integration into the cellular genome, 
Class 2 inhibits expression of viral genes and Class 3 inhibits production of new virions once 
integration and expression has taken place (von Laer, Hasselmann et al. 2006). According to 
predictions from mathematical modelling, as discussed in section 3.1, Class 1 gene therapies 
are likely to be the most effective as they inhibit HIV at the first steps, and provide a 
selective advantage to these cells by avoiding any viral or immunological induced death 
from infection. Hence many gene therapeutics currently under investigation include 
components that impair attachment or fusion stages of the viral life-cycle (Symonds, 
Johnstone et al. 2010).  
While all these classes are potential HIV gene therapeutics, practically, the use of multiple 
therapeutics in combination is likely to be the most effective method. This is analogous to 
the antiretroviral situation where it does not take long for HIV resistance to emerge against 
single antiretroviral drugs. These antiretroviral drugs have been shown to be far more 
effective when used in combination. It is for this reason that gene therapy research has often 
been focused on the use of multiple gene therapuetics used in conjunction with one-another. 
As well as the variety of targets being investigated, there is additionally a wide range of 
methods to achieve inhibition of these targets. The most commonly employed methods to-
date include the following:   
Antisense (Class 2): Antisense RNA is a synthetic nucleotide sequence that binds to mRNA 
in order to inhibit its function. This method can be used against a wide range of targets, 
including the HIV envelope (Levine, Humeau et al. 2006). 
Aptamers (Class 2 or 3): Aptamers are single-stranded RNAs or DNAs. They disrupt at the 
protein level by tightly binding to their target ligand (Que-Gewirth and Sullenger 2007). 
Aptamers can be used to target a wide array of proteins and as such have potential to be 
used in multiple settings. 
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Fig. 1. The three Classes of gene-therapy according to cycle of HIV infection inhibited as 
defined by von Laer et al(von Laer, Hasselmann et al. 2006; von Laer, Hasselmann et al. 
2006). Class 1 inhibits all steps in the infection cycle prior to integration of the HIV RNA into 
the cellular genome. In particular, Class 1 inhibits either the entry of the HIV virion into the 
cell (i.e. inhibition of attachment/integration of the HIV virion through the CD4, CCR5 and 
X4 receptors/coreceptors) or inhibits integration into the cellular genome once a virion has 
entered the cell (i.e. blocks uncoating, reverse transcription or integration). Class 2 inhibits 
gene expression and the production of structural components required for the assembly of 
new HIV virions. Class 2 also results in lower susceptitibliy to cell death through the 
cytotoxic T lymphocyte (CTL) immune response, as a result of reduced recongnition via the 
Major Histocompatiblity Complex (MHC). Finally, Class 3 inhibits the assembly and export 
of virions from the infected cell. 
Intracellular Antibodies (Class 1 or 3): Intracellular antibodies, or “intrabodies”, are 
designed to bind to and inactivate target molecules inside host cells (Chen, Bagley et al. 
1994). One target which has been used by intrabodies is CCR5, whereby the intrabodies bind 
to CCR5 and block surface expression (Rossi, June et al. 2007). 
Ribozymes (Class 2): Ribozymes are catalytic RNA molecules that have the ability to 
degrade RNA in a sequence-specific manner (Sun, Wang et al. 1995). When used as anti-HIV 
agents, they have the potential to target multiple steps, affecting incoming RNA (during 
infection, in this sense they can act in part as Class1), primary RNA transcripts (from 
integrated provirus), spliced mRNAs and mature RNA being packaged into virions. These 
are primarily Class 2 inhibitors and examples are those designed to target the conserved 
regions of HIV such as the overlapping regions of vpr and tat reading frames (Mitsuyasu, 
Merigan et al. 2009). Highly conserved regions are desirable as targets so that sequence 
specificity is more likely to be maintained. 
Short hairpin RNA (Class 1 or 2): Short hairpin RNA is a sequence of RNA that folds back 
upon itself in a hairpin turn; it can be used to initiate RNA interference and consequently 
silence gene expression (McIntyre and Fanning 2006). shRNA expression vectors utilise a 
promoter to drive expression of the shRNA. As an integrated vector, this expression cassette 
will be passed on to daughter cells, allowing the gene silencing to be maintained in vivo. The 
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shRNA hairpin structure is cleaved by the cellular machinery into siRNA which is then 
bound to the RNA-induced silencing complex. This complex binds to and cleaves mRNAs 
which match the siRNA that is bound to it (Hannon and Rossi 2004). The use of siRNA for 
gene silencing has become a method of choice and can be potentially applied to  many 
targets, including down-regulation of CCR5 that will decrease target cell infectivity by HIV 
and other host receptors as the removal or impairment of these receptors will render HIV 
non-infectious (Class 1). 
 
Class Target Site Why Goal How 
1 CCR5 Important  
co-receptor 
Remove/prevent 
expression of CCR5 
Zinc-finger, 
siRNA 
1 CD4 Essential 
receptor for HIV 
attachment 
Remove/prevent 
expression of CD4 
Zinc-finger, 
siRNA 
1 CXCR4 Important  
co-receptor 
Remove/prevent 
expression of CXCR4 
Zinc-finger, 
siRNA, ribozyme 
1 Membrane 
Fusion 
(HIV 
heptad 
repeat) 
Essential for viral 
entry 
Prevent entry of HIV 
through host-cell 
membrane 
siRNA 
2 Tat Important for 
Transcription 
Disrupt tat gene Tar decoy, 
siRNA, ribozyme 
2 Rev Important for 
virion 
Translation 
Disrupt rev gene siRNA, REV 
mutants 
3 Env, 
Protease, 
Helicase 
Important for 
virion 
maturation 
Prevent virion 
maturation 
siRNA, 
Antisense RNA,  
3 Gag Important for  
virion assembly 
Disrupt gag gene Ribozyme, 
siRNA 
Table 1. A list of some HIV gene therapy targets, the goals and the mechanics of how they 
are being explored. This table shows a variety of Class 1, 2 and 3 therapies and the range of 
approaches against targets. 
Fusion Inhibitors (Class 1): One fusion inhibitor which has been researched in detail is the 
maC46 peptide (C46) (Zahn, Hermann et al. 2008). It inhibits viral fusion by interacting with 
the N-terminal hydrophobic alpha-helix. This prevents changes essential for membrane 
fusion of the virus and host cell. This fusion inhibitor has been found to be highly effective 
at blocking HIV replication (Zahn, Hermann et al. 2008). 
Zinc Finger Nucleases (ZFNs) (Class 1 or 2): ZFNs bind to targeted open reading frames. 
Two juxtaposed ZFN’s on DNA results in dimerisation of the endonuclease domains, 
generating a double-stranded break at the targeted DNA (Porteus and Carroll 2005). The 
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mutagenic pathways relied on to repair the DNA breaks result in nucleotide mutations at 
the break-sites, thus permanently disrupting the gene (Porteus and Carroll 2005). While 
experiments in mice have shown this method to be effective, there is still a risk of non-
target directed mutagenesis. Another limitation of this technique is the inability to add 
protective genes, as only the effective deletion/inactivation of genes can be performed, 
thus limiting the applications for the use of ZFNs to applications such as inactivation of 
CCR5 (Class 1). 
2.2.2 Strong arguments for gene-therapy based entry inhibition 
Class 1 inhibitors generally act at the level of HIV binding to the target cell (von Laer, 
Hasselmann et al. 2006). It is expected that this would be the most effective as HIV is 
blocked from entry to the target cell and any subsequent replication steps cannot take place. 
An important recent contribution to the argument for Class 1 inhibitors is the discovery of 
the cause of the so-called ‘bystander effect’ where apparently non HIV infected cells also 
succumb to HIV pathogenesis (Doitsh, Cavrois et al. 2010). The observation that 
productively infected cells are not the only contributors to host-cell death has been noted 
previously, however the cause of this cell death had remained unknown until Doitsh et al 
discovered abortive/nonproductive HIV infection in host-cells (approximately 95% of 
infected cells) and the induction of apoptosis in these cells (Doitsh, Cavrois et al. 2010). This 
“bystander effect” is likely to have contributed to the lack of success of some antiretroviral 
therapy methods, including a variety of clinical trials whereby HIV infection was only 
inhibited after HIV entry, as host-induced apoptosis would greatly reduce the effectiveness 
of treatment. This effect indicates a crucial additional benefit of entry-inhibitors over other 
classes of antiviral treatment. 
One of the resistance mechanisms developed by HIV against the antiretroviral CCR5 
antagonists, such as maraviroc, is not just the use of other co-receptors such as CXCR4, it is 
the use of maraviroc-bound CCR5 receptors (Westby, Smith-Burchnell et al. 2007). This 
mechanism of resistance would not be available against cells containing a down-regulation, 
or mutation-mediated deletion of the CCR5 receptor produced by gene therapy. An added 
bonus of the use of attachment and/or fusion inhibitors is that they do not provide cross-
resistance with other treatment methods such as protease and integration inhibitors. 
2.3 Vectors, delivery methods and promoters: Delivering the protective gene into the 
cell 
The therapeutic used in gene therapy must be carried within a suitable vector or delivery 
system; for HIV gene therapy these vectors should generally be capable of integrating into 
the host cells with minimal risk of generation of replication competent lentivirus or 
insertional mutagenesis (Wu, Wakefield et al. 2000; Symonds, Johnstone et al. 2010). The 
vector must also be non-toxic to the host while allowing the expression of the relevant 
gene(s). There are many techniques and delivery vectors which can be utilized for this 
purpose. Examples of the most commonly used delivery vectors are shown in Table 2. 
Transposon-based delivery systems consist of a synthetic transposon and an associated 
transposase and work via a cut-and-paste mechanism whereby the transposase recognises 
the inverted direct sequences in the transposon, and then the transposon is excised and later 
integrated into a target DNA region (Tamhane and Akkina 2008). They can, for example, be 
used to carry shRNAs. 
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Delivery 
Vector 
Advantage Disadvantage 
Transposons Can provide permanent expression of 
multiple genes 
Potential for insertional 
mutagenesis 
Plasmid DNA 
Nucleofection 
Treatment has been highly effective 
(Holt, Wang et al. 2010) 
Slight increase in apoptosis of HSCs 
(Holt, Wang et al. 2010) 
Murine 
Leukaemia 
Virus 
Little/no adverse effects (Amado, 
Mitsuyasu et al. 2004; Macpherson, 
Boyd et al. 2005) 
Can only infect actively replicating 
cells (Roe, Reynolds et al. 1993) 
May induce insertional mutagenesis 
(Symonds, Johnstone et al. 2010) 
Adenovirus Can infect non-replicating cells 
(Zhang, Sankar et al. 1998) 
Innate immune response (Liu and 
Muruve 2003) 
Lentivirus Can infect non-replicating cells 
(Zufferey, Dull et al. 1998), Does not 
effect proliferation or differentiation 
of HSCs (Gervaix, Schwarz et al. 1997)
Slight risk of insertional 
mutagenesis (Philippe, Sarkis et al. 
2006) 
Conditionally 
replicating 
virus 
Higher transduction efficiency Risk of mutation/recombination 
Table 2. A variety of commonly used delivery vectors and their associated advantages and 
disadvantages. 
Nucleofection of DNA involves directly adding the DNA into the targeted cells by 
disrupting the cell membrane through electroporation. While this is not an ever-present 
biological vector as those mentioned above, it is more of an event-based vector which can 
provide a method of entry either for less entry-capable vectors, or plasmid DNA (Aluigi, 
Fogli et al. 2006). 
Viral delivery vectors are typically made from the backbone of suitable viruses, whereby 
pathogenic, and (often) replication-mediating genes are removed, and only the essential 
genes remain (Kootstra and Verma 2003). The therapeutic gene(s) being used is/are then 
added to the viral backbone. The virus is then able to infect host cells as would its natural 
counterpart. However without the ability to replicate or express harmful genes. It is used 
only to integrate into the host genome and allow the therapeutic gene to be active. 
One of the main concerns regarding gene therapies is the potential for insertional 
mutagenesis. This has been shown to occur in SCID-X1 trials (Howe, Mansour et al. 2008) 
where the insertional mutagenesis led to myeloproliferation/leukemia (Howe, Mansour et 
al. 2008). While insertional mutagenesis events have occurred in this and a few other gene 
therapy trials eg CGD (Stein, Ott et al. 2010), they have not occurred in HIV gene therapy 
trials, and a great deal of effort is undertaken to ensure that this event does not occur. 
To ensure efficient transcription of the therapeutic gene, a suitable promoter is required. A 
promoter is a region of DNA that facilitates the transcription of nearby downstream gene(s), 
and is essential for the efficient expression of the desired gene(s). The choice of the promoter 
to be used in gene therapies is highly important, and various promoters have been tested in 
laboratory studies and clinical trials. Promoters currently in use in HIV gene therapy studies 
www.intechopen.com
 
Recent Translational Research in HIV/AIDS 
 
412 
are quite diverse and include U6 (human derived), T7 (bacteriophage derived), and Ubc 
(Human ubiquitin c) (Anderson, Banerjea et al. 2003; Boden, Pusch et al. 2003; Weber and 
Cannon 2007): 
There have been studies using different promoters in HIV gene therapy work-up and many 
have been shown to be effective. However, due to the many different therapeutic genes, 
their delivery vectors, and the cells targeted for transduction, it is difficult to determine 
which promoters are the most effective and as such, each needs to be tested. 
It has been noted that a highly expressive promoter may not be the ideal candidate, as 
many highly efficient promoters can have other side-effects. As noted above, of key 
concern is the trans-activation (insertional mutagenesis) of nearby cellular genes (Weber 
and Cannon 2007), potentially leading to oncogenic effects by over-expression of 
important proteins. 
2.4 Transduction targets: Which cells should be protected against HIV? 
HIV infection is typically characterized by CD4+ T cell infection and depletion. In addition, 
other cells are also infected by HIV, including macrophages and monocytes and most 
recently there have been reports of hematopoietic stem cell (HSC) infection (Stanley, Kessler 
et al. 1992; Carter, Onafuwa-Nuga et al. 2010; Carter, McNamara et al. 2011). In the case of 
gene therapy for HIV the two most common cell types that have been transduced to date 
with the therapeutic relevant gene are CD4+ T lymphocytes and HSC. Transduction of these 
cells is expected to provide the best outcome due to CD4+ T cells being the main targets of 
HIV infection and the ability of HSC to differentiate into all susceptible cells. In this 
subsection we discuss the biological aspects of transducing either CD4+ T cells or HSC with 
a protective gene. 
 
 
Fig. 2. Two ways of achieving cell populations protected against HIV as a result of either 
transducing CD4+ T cells or HSC. If the CD4+ T cell population is transduced with a 
protective gene (left), then protection against HIV is only afforded to CD4+ T cells. If on the 
other hand HSC are transduced with a protective gene (right), then the protected gene is 
retained by all cells derived from the HSC via differentiation through the myeloid (e.g 
macrophage) and lymphoid lineages (e.g CD4+ T cell). The approach of transducing HSC 
thus provides protection against HIV to a broader class of cells. 
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2.4.1 Transduction of CD4+ T cells 
The use of CD4+ T cells as target cells for HIV gene therapy has been explored in several 
studies (see section relating to clinical trials). Isolation and transduction of CD4+ T cells is 
relatively simple. The key advantage of targeting CD4+ T cells is the ease with which they 
may be accessed. As they largely populate and regularly traffic through peripheral blood, no 
stimulatory factors are required to mobilize them prior to collection. Conceptually it can be 
envisaged that the introduction of a protected population of CD4+ T lymphocytes should 
have impact as these are the cells specifically depleted by HIV infection; the greater the 
severity of HIV infection the greater the CD4+ T lymphocyte decline.  
One such study involving the therapy of CD4+ T cells was performed by Levine in 2006 
(Levine, Humeau et al. 2006) whereby peripheral blood CD4+ T cells were harvested from 
each subject by apheresis. The collected samples were then depleted of CD8+ cells and 
monocytes, transduced with the gene construct ex vivo, activated via CD3 and CD28 
costimulation and expanded before being re-infused into the patients. This method of 
therapy was shown to be both safe in treatment, and effective in delivery of the therapeutic 
gene (Levine, Humeau et al. 2006; Brunstein, Miller et al. 2011). 
Predicted in-vivo dynamics of CD4+ T cell transduction, based on mathematical modelling, 
are discussed in section 3.2.1. 
2.4.2 Transduction of hematopoietic stem cells (HSC) 
Due to the range of cells which HIV infects, it is thought to be a significant advantage to 
transduce HSC, as these cells provide a continuous supply (following differentiation) into a 
range of immunological cells (monocytes, macrophages, CD4+ T cells, CD8+ cells, dendritic 
cells, microglial cells) which may thus be protected against HIV infection (Carter and 
Ehrlich 2008). A delay in the newly ‘protected cell’ production would be expected, thus 
delaying the effect of the therapeutic gene(s). However, there can still be a significant 
production of CD4+ T lymphocytes, the supply of which has been predicted to be a rate of 
approximately 1.65 cells/µL of blood/day (due to thymic reconstitution) (Murray, 
Kaufmann et al. 2003). This results in the production of a stable population of protected cells 
which could impact on CD4+ T cell number and viral load. 
While CD4+ T cells (and other cell types common in peripheral blood) can be obtained 
relatively simply prior to transduction by apheresis from peripheral blood, HSC must first 
be mobilised from the bone marrow (discussed in detail below). This creates an additional 
component to the treatment process. Currently the most common method for the 
mobilisation of HSC is the use of granulocyte colony stimulating factor (G-CSF), a treatment 
that usually spans 4-5 days before the apheresis of peripheral blood can begin. Predicted in-
vivo dynamics of HSC transduced with a protective gene are discussed in section 3.2.2. 
2.5 Collection of cells for transduction: Apheresis and treatment methods for 
optimized and high-volume cell collection 
Current gene therapy protocols for HIV require the isolation of the relevant cells to be 
transduced, generally following apheresis (Symonds, Johnstone et al. 2010). Apheresis is the 
process of removing mononuclear cells from blood and returning neutrophils, platelets, 
plasma and red blood cells to the donor, in order to collect more of one particular part of the 
blood than could be separated from a unit of whole blood. Apheresis allows for the 
collection of large quantities of cells, and in the case of gene therapies for HIV, total 
lymphocytes, CD4+ cells, or HSC are the cell types collected. 
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It is common practice to use a stimulating agent such as G-CSF in order to increase the 
quantity of HSC in the peripheral blood. The resulting increase in cell numbers in peripheral 
blood is due to redistribution of cells from other compartments of the body (i.e bone 
marrow and lymph tissue). The use of G-CSF and other stimulating factors  is essential 
when HSC (largely inhabiting the bone marrow) are to be transduced with the therapeutic 
gene. Various trials have shown HSC cell counts in peripheral blood increase 20-50-fold 
over the course of GCSF administration (Lane, Law et al. 1995; Law, Lane et al. 1999; 
Valgimigli, Rigolin et al. 2005). 
 
 
Fig. 3. Illustration of the clinical aspects of therapeutic apheresis (for HSC harvesting), and 
the subsequent processes of transduction and reinfusion. The HIV infected individual is first 
administered G-CSF in order to effect mobilization of HSC from bone marrow into 
peripiheral blood. The mobilized HSC are then collected from peripheral blood and 
subsequently transduced with a protective gene. The transduced HSC are then reinfused 
into the patient. 
A technique known as myeloablation has been utilized in some clinical trials (before the 
transduced cell infusion) in order to improve engraftment of the gene-containing cells 
(Strayer, Akkina et al. 2005). This procedure involves the killing of HSC, thereby reducing 
the endogenous non-transduced cells, thereby creating more space for the transduced cell 
population. 
2.6 Important studies involving gene-therapy: Promising results and insights 
Several mouse studies and clinical trials have been conducted in the area of HIV gene 
therapy, with several different therapuetic targets. 
Transduction with
Therapeutic Gene
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Target/Mechanism 
of Action 
Construct Results Reference 
Rev  Inhibitory Rev protein, 
Rev M10, delivered to 
CD4+ cells by gold 
particles 
Preferential survival of cells 
with construct. Limited 
duration of engraftment. 
(Woffendin, 
Ranga et al. 
1996) 
Rev  Inhibitory Rev protein, 
Rev M10, delivered to 
CD4+ cells by retroviral 
vector 
More persistent engraftment 
compared with gold particle 
delivery. No change  
(Ranga, 
Woffendin et 
al. 1998) 
Rev  “Humanized” dominant-
negative REV protein 
(huM10) and 
nontranslated marker 
gene (FX) as an internal 
control in retroviral 
vector 
Gene marking in first 
months, then low or 
undetectable except in one 
patient when viral load 
increased. No serious 
adverse events. 
(Podsakoff, 
Engel et al. 
2005) 
rev/TAR  Trans-dominant rev with 
or without antisense TAR 
and control (neo) gene in 
CD4+ T lymphocytes   
Long term survival of cells 
at low level. Preferential 
survival of gene-containing 
cells in a patient with high 
viral load. 
(Morgan, 
Walker et al. 
2005) 
RRE decoy Retroviral-mediated 
transfer of an RRE decoy 
gene into bone marrow 
CD34+ cells  
No adverse effects. 2  
subjects’ cells detected 
containing both the RRE and 
LN vectors on the day after 
cell infusion. All subsequent 
samples negative for the L-
RRE-neo vector. Cells 
containing the control LN 
vector detected up to 330 
days.  
(Kohn, Bauer 
et al. 1999; 
Bauer, 
Selander et al. 
2000) 
Env antisense  Single infusion of 
VRX496TM, a lentiviral 
construct encoding an 
antisense targeting HIV 
env, in CD4+ T cells 
CD4+ counts increased in 
4/5 patients, viral loads 
stable, prolonged 
engraftment. Well tolerated. 
Transient vector 
mobilization. Safe to date. 
(Levine, 
Humeau et al. 
2006) 
rev/tat ribozyme  tat and tat/rev ribozyme 
in CD34+cells in 
autologous CD34+ cells 
and empty vector 
backbone in two patient 
groups with and without 
ablation 
Trial 1 - 3/5 patients showed 
low-frequency marking of 
PBMC with ribozyme and 
vector backbone. Trial 2 – 
gene marked cells detected 
after infusion and to one 
year, and RNA expression 
detected. 
(Michienzi, 
Castanotto et 
al. 2003) 
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Target/Mechanism 
of Action 
Construct Results Reference 
tat/vpr ribozyme  Phase I study: Moloney 
murine leukaemia 
retroviral vector encoding 
a ribozyme  vs control 
LNL6 vector in CD34+ 
HPSC 
de novo production of 
myeloid and lymphoid cells. 
Degree of persistence of 
gene-containing cells 
dependent on transduced 
cell dose 
(Amado, 
Mitsuyasu et 
al. 1999; 
Amado, 
Mitsuyasu et 
al. 2004) 
tat/vpr ribozyme  Retroviral vector 
encoding a ribozyme  vs 
control LNL6 vector to 
transduce T lymphocytes, 
predominantly CD4+ T 
lymphocytes 
Safe and feasible procedure. 
Long-term survival of 
genetically modified T-
lymphocytes. 
(Macpherson, 
Boyd et al. 
2005) 
tat/vpr ribozyme  Phase II study: Moloney 
murine leukaemia virus-
based, replication-
incompetent gamma 
retroviral vector with 
gene encoding a 
ribozyme vs placebo in 
CD34+ cells 
No significant difference 
mean plasma viral load at 
primary end-point but lower 
TWAUC. No safety 
concerns. 
(Mitsuyasu, 
Merigan et al. 
2009) 
Fusion inhibitor  Gene encoding 
membrane anchored 
peptide C46 fusion 
inhibitor delivered by 
retroviral vector in T 
cells.  
Increased CD4. No 
significant change in viral 
load (except after treatment 
change). Modified cells 
detected at one year. Low 
level marking. No major 
toxicity 
(van Lunzen, 
Glaunsinger et 
al. 2007) 
CCR5 CCR5-specific zinc finger 
nuclease based product, 
SB-728-T, in autologous 
CD4+ T cells. Two phase 
1 trials with various 
dosing regimens in 
different patient groups. 
Preliminary data on 1 
patient only  ZFN-modified 
cells persisted in circulation 
and observed in GALT. 
Suggested delay in return of 
viral load after structured 
treatment interruption. 
(2009) 
Tat/rev, CCR5, 
TAR decoy 
Tat/rev short hairpin 
RNA, TAR decoy and 
CCR5 ribozyme 
expressed from a self-
inactivating lentiviral 
vector transduced in 
CD34+ cells, along with 
standard unmanipulated 
HPCs  in 4 patients with 
HIV and non-Hodgkin’s 
lymphoma 
Engraftment by 11 days. 
Low levels of gene marking 
observed up to 24 months as 
was expression of siRNA 
and CCR 
(DiGiusto, 
Krishnan et al. 
2010) 
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Target/Mechanism 
of Action 
Construct Results Reference 
 Modified T-cell 
receptor 
Autologous infusion of 
CD4+ and CD8+ T cells 
modified by CD4ζ in a 
murine moloney 
leukaemia virus 
backbone given +/- IL-2. 
Gene-modified cells 
followed and detected to 12 
months with no difference 
due to IL-2. No significant 
change in plasma viral load. 
CD4ζ signal detected in 
rectal biopsy.  
(Mitsuyasu, 
Anton et al. 
2000) 
Table 3. (Apapted from Symonds et al (Symonds, Johnstone et al. 2010)): A list of HIV gene 
therapy clinical trials and their outcomes. Each of these studies vary in their gene therapy 
target, and method of targeting the specific region. 
To date, as shown in Table 3, several different gene therapies have entered Phase 1 clinical trials, 
(and some into Phase 2) indicating the safety of a range of HIV gene therapeutics including 
antisense, ribozymes, decoys, intracellular antibodies and zinc fingers targeting CCR5. 
3. Protective effects of anti-HIV gene-therapy: Predictions from mathematical 
modeling 
In gene-therapy research, mathematical modelling has been employed to predict the 
protective effects of anti-HIV gene-therapy (von Laer, Hasselmann et al. 2006; von Laer, 
Hasselmann et al. 2006). In this section we review current results on mathematical 
modelling, with respect to predictions of the in-vivo anti-HIV protective effects. 
Mathematical models deal with the complex interactions between gene-therapy, the 
immune system and HIV infection (Perelson, Essunger et al. 1997). Given the relative 
sparsity of current clinical trial data of gene-therapy for HIV, and the long time-spans over 
which predictions are to be made (i.e. over many years) mathematical modelling can 
provide predictions on the likely in-vivo effectiveness of current and future gene-therapies. 
Modelling work to-date has led to important insights regarding key design factors as well as 
parameters that should be optimized in order to maximize the effectiveness of therapy (von 
Laer, Hasselmann et al. 2006; von Laer, Hasselmann et al. 2006). In this section we review 
current results and key insights. 
3.1 Why is Class 1 gene-therapy the most promising approach? 
As discussed previously, three different broad stages of the HIV infection cycle may be 
targeted for inhibition of HIV infection (Figure 1) with the inhibitors referred to as Class 1, 2, 
and 3 (von Laer, Hasselmann et al. 2006; von Laer, Hasselmann et al. 2006). It is of interest 
whether inhibiting earlier stages (via Class 1), intermediate stages (via Class 2) or later 
stages (via Class 3) of the infection cycle might provide maximum effectiveness of the 
therapy. Is it more desirable to prevent HIV entry and integration into the cellular genome 
via Class 1, to inhibit the production of structural components for HIV assembly via Class 2, 
or to inhibit the assembly/export of new HIV virions via Class 3? This question has been 
addressed by a number of investigators (von Laer, Hasselmann et al. 2006; von Laer, 
Hasselmann et al. 2006; Applegate, Birkett et al. 2010), subject to a variety of modelling 
assumptions reflecting differing levels of complexity of the interaction between HIV, gene-
therapy and the immune system.  
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Investigations to-date have demonstrated that Class 1 protection appears to be highly 
desirable  in terms of reducing viral loads and increasing CD4+ T cell counts (von Laer, 
Hasselmann et al. 2006; Applegate, Birkett et al. 2010; Aviran, Shah et al. 2010). The 
underlying reason for the superiority of Class 1 therapy (over Class 2 and Class 3) has 
been attributed to the high selective advantage of the protected cell population conferred 
by Class 1 inhibition (von Laer, Hasselmann et al. 2006; von Laer, Hasselmann et al. 2006; 
Applegate, Birkett et al. 2010). Since Class 1 inhibits all steps prior to viral integration into 
the cellular genome (Figure 1), any cell containing the protective gene is less likely to be 
infected than a non-protected cell. Consequently, Class 1 promotes the survival and 
expansion of the protected non-infected cells, whereas the non-protected cells are more 
prone to infection and selective killing through cytopathic effects associated either with 
the virus or the CTL immune response (von Laer, Hasselmann et al. 2006; von Laer, 
Hasselmann et al. 2006). 
In contrast to Class 1 agents, Class 2 and Class 3 therapies have been shown to require much 
higher degrees of inhibition in order to achieve clinically significant effects (von Laer, 
Hasselmann et al. 2006; von Laer, Hasselmann et al. 2006; Applegate, Birkett et al. 2010). 
Class 2 inhibits cytopathic effects associated with the viral infection and the CTL immune 
response (Figure 1). Any infected cell with Class 2 protection is therefore longer-lived and 
also has a reduced viral production rate compared to an unprotected and infected cell (von 
Laer, Hasselmann et al. 2006; von Laer, Hasselmann et al. 2006; Applegate, Birkett et al. 
2010). Class 2 consequently confers a selective survival advantage to the infected cells 
containing the protective gene relative to other infected cells, but not to non-infected cells 
containing the protective gene (as is the case with Class 1). In contrast, Class 3 only inhibits 
the export of new HIV virions from an infected cell and thus provides minimal selective 
advantage (von Laer, Hasselmann et al. 2006; von Laer, Hasselmann et al. 2006). Hence 
Class 1 is the only class that confers a selective survival advantage to non-infected cells 
containing the protective gene (von Laer, Hasselmann et al. 2006; von Laer, Hasselmann et 
al. 2006; Applegate, Birkett et al. 2010).  
Collectively therefore, modelling work to-date implies that Class 1 is essential due to the 
selective survival advantage conferred to the protected and non-infected cells. Still, it is 
important to note that augmenting Class 1 with Class 2 and/or Class 3 protection might 
further increase the effectiveness of therapy (von Laer, Hasselmann et al. 2006; von Laer, 
Hasselmann et al. 2006; Applegate, Birkett et al. 2010). Recent findings relating to the 
“Bystander Effect”, as discussed previously in section 2.2.2, have lent further support to 
arguments relating to Class 1 inhibition (Doitsh, Cavrois et al. 2010), as abortive infections 
(HIV virion enters the cell, but does not integrate into cellular genome) comprise  95% of all 
cell death resulting from HIV infection.  
3.2 Two different transduction approaches: To transduce CD4+ T cells or HSC with a 
protective gene? 
As discussed previously in section 2.4, it is possible to either transduce CD4+ T cells with a 
protective gene (for an immediately protected population of CD4+ T cells) or to transduce 
HSC, that provide protection to CD4+ T cells following differentiation through the 
lymphoid line and to monocyte/macrophages following differentiation throught the 
myeloid line. While the relative merits of each approach have attracted substantial interest, 
the long-term quantitative  advantages and disadvantages of each approach in the clinical 
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setting remain to be elucidated. Consequently, investigators have turned to predictions from 
mathematical modelling in order to shed light on the in-vivo dynamics of the two 
approaches. In this section, we review the predictions from such modelling work to-date.  
3.2.1 Transducing CD4+ T cells with a protective gene: Can we achieve establishment 
of a sufficiently large and sufficiently “receptor-diverse” CD4+ T cell population that 
is protected against HIV? 
Expansion of numbers of CD4+ T cells containing a protective gene is subject to the rate-
limiting step of homeostatic cell division and proliferation (von Laer, Hasselmann et al. 
2006). Thus it is important to determine how quickly a substantial CD4+ T cell population 
could expand from a small initial fraction of protected cells. Such considerations are 
motivated by the fact that it is currently feasible and practical to transduce only a portion of 
the total CD4+ T cell population (Dropulic and June 2006; von Laer, Baum et al. 2009), so 
that expansion of the protected CD4+ T cell population will have to rely on in vivo 
mechanisms.  
While modelling has shown that a small fraction of initially transduced cells could 
potentially result in significant expansion of the protected CD4+ T cell population, 
reductions of viral load, and also a delay in the onset of AIDS (Lund, Lund et al. 1997; 
Leonard and Schaffer 2006; von Laer, Hasselmann et al. 2006; Aviran, Shah et al. 2010), most 
of these models have assumed a strong feedback mechanism upregulating cellular 
proliferation when numbers fall below a normal level. Whereas such homeostatic 
mechanisms are believed to contribute to the maintenance of T cell numbers in healthy 
individuals (Khaled and Durum 2002), the speed with which they occur is likely to be 
significantly slower in practice. Current clinical trials have not produced CD4+ T cell 
expansions at rates as fast as predicted by mathematical modelling (Dropulic and June 2006; 
von Laer, Baum et al. 2009).  
Current estimates of T lymphocyte division put the normal rate at approximately 1 
division every 3.5 years for naive T cells and 1 division every 22 weeks for memory T 
cells (McLean and Michie 1995). If the transduced CD4+ T cells are to expand in vivo, 
then such time-scales should provide an indication of the slow nature of any in vivo 
expansion of the transduced CD4+ T cell population unless driven by strong selective 
pressure by HIV. 
More realistic upper bounds on rates of CD4+ T cell expansion in-vivo under gene-therapy 
may be obtained by consideration of CD4+ T cell reconstitution on HAART (Byakwaga, 
Murray et al. 2009). Reconstitution of the CD4+ T cell population under HAART appears 
relatively slow with average increases of approximately 300 cells/µL observed after about 6 
years (Byakwaga, Murray et al. 2009). Given that reconstitution on HAART usually only 
takes place under complete viral suppression (as opposed to gene-therapy where a 
measurable viral population may be present), it appears likely that the expansion rates of 
the protected CD4+ T cell population under gene-therapy may be substantially slower. 
Unlike the situation with HAART high viral levels may be preferable in early stages of gene 
therapy to act as a driving force for the expansion of a protected CD4+ T cell population via 
a selective mechanism. 
Several additional factors might further inhibit the expansion of the protected CD4+ T cell 
population in-vivo. First, unless sufficient selective survival advantage is conferred to the 
protected CD4+ T cell population, the protected cell population might not expand 
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substantially in-vivo. Second, the transduced CD4+ T-cells might have increased death rates 
or decreased proliferative ability due to interference of the protective gene with normal cell 
functionality (Dropulic and June 2006; von Laer, Baum et al. 2009; Tayi, Bowen et al. 2010). 
Third, the unprotected de-novo CD4+ T-cells exported from the thymus might effectively 
dilute the transduced CD4+ T-cells in the periphery (Aviran, Shah et al. 2010). This latter 
problem may potentially be addressed by subsequent “booster” treatments involving 
repeated infusions of transduced CD4+ T cells or by also using HSC. 
An additional disadvantage associated with the direct transduction of CD4+ T cells is that 
peripheral expansion of their number does not necessarily correspond to an equivalent 
expansion in the T cell repertoire (Nikolich-Zugich, Slifka et al. 2004; Allen, Turner et al. 
2011; Wiegers, Kaufmann et al. 2011). This is important as any resulting “gaps” in the T cell 
repertoire may result in increased probability of immune system evasion by pathogens and 
consequently in increased risk of infection or morbidity (Nikolich-Zugich, Slifka et al. 2004; 
Allen, Turner et al. 2011; Wiegers, Kaufmann et al. 2011).  
Hence although direct transduction of CD4+ T cells results in a faster appearance in 
peripheral blood of a protected component of this susceptible population, there may be 
disadvantages in that these may not provide a diverse immune response and other cell 
populations will not protected. 
3.2.2 Transducing HSC with a protective gene: Increasing T cell receptor repertoire 
and broadening class of protected cells. 
An alternative to transducing CD4+ T cells directly is to instead transduce HSC. In this case, 
the production of de-novo CD4+ T cells containing the protective gene occurs as a result of 
HSC differentiation through the lymphoid line and subsequent export from the thymus 
(Symonds, Johnstone et al. 2010).  
 
 
Fig. 4. Modelling predictions by Murray et al.(Murray, Fanning et al. 2009) regarding 
comparison of the scenario that 20% of all HSC in the bone marrow are transduced with a 
tat-vpr specific anti-HIV ribozyme (OZ1) versus the scenario that no gene-therapy treatment  
is received. Reproduced with permission from Murray et al.(Murray, Fanning et al. 2009). 
The patient was assumed  HAART-naive. The time-scale on the horizontal ordinate denotes 
the time since receiving gene-therapy at year 0. (A) Treatment with OZ1, log10 HIV RNA 
copies/ml (solid line); No treatment, log10 HIV RNA copies/ml (dashed line). (B) Treatment 
with OZ1, total CD4+ T lymphocytes/mm3 (solid line), OZ1+CD4+ T lymphocytes/mm3 
(dash–dot line); No treatment , total CD4+ T lymphocytes/mm3 (dashed line).  
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Transducing HSC with a protective gene has two distinct advantages. First, the export of 
protected de-novo CD4+ T cells from the thymus results in a diversification of the T cell 
receptor repertoire (Allen, Turner et al. 2011; Wiegers, Kaufmann et al. 2011). Consequently 
the expanded CD4+ T cell population containing the protective gene exhibits more 
“extensive” TCR coverage over time, reducing the risk that pathogens might evade the 
immune response (Nikolich-Zugich, Slifka et al. 2004; Allen, Turner et al. 2011; Wiegers, 
Kaufmann et al. 2011). Secondly, HSC differentiate into a broad range of cells (besides CD4+ 
T cells), including macrophages that are susceptible to HIV infection and that may represent 
important latent HIV reservoirs (Chun, Carruth et al. 1997; Chun, Stuyver et al. 1997; Crowe 
and Sonza 2000). Consequently, HSC transduction provides protection against HIV to a 
broader class of cells than just CD4+ T cells. 
The transduction of HSC does not immediately provide a protected population of CD4+ T 
cells in the periphery, but rather the protected CD4+ T cell population is established 
relatively slowly as HSC differentiate and are exported from the thymus (Symonds, 
Johnstone et al. 2010). Thymic production of CD4+ T cells has been estimated at 
approximately 1.65 cells/µL/day (Murray, Kaufmann et al. 2003) in peripheral blood. 
Assuming that a percentage P of total HSC in the bone marrow is transduced, then one 
would correspondingly expect that CD4+ T cells containing the protective gene would be 
exported at a rate of 1.65 x P cells/µL/day from the thymus (Murray, Fanning et al. 2009). 
Such numbers provide estimates of rates at which the establishment of a protected CD4+ T 
cell population might take place in-vivo in peripheral blood.  
Achieving high engraftment efficiencies of HSC in the bone marrow is important. While a 
number of clinical trials in which HSC were transduced reported indications of clinical effect 
against HIV (Symonds, Johnstone et al. 2010), engraftment percentages in the bone marrow 
have been relatively low (Dropulic and June 2006; Mitsuyasu, Merigan et al. 2009; von Laer, 
Baum et al. 2009; Symonds, Johnstone et al. 2010). Such results underscore the need for more 
effective methods of cell harvesting, transduction and homing, that achieve higher 
engraftment efficiencies. Increased engraftment percentages should lead to more substantial 
clinical effects in terms of protection against HIV (Mitsuyasu, Merigan et al. 2009; Murray, 
Fanning et al. 2009). 
Despite relatively low engraftment efficiencies to-date, it is of practical interest for future 
research directions to determine what engraftment percentages might suffice for clinically 
meaningful effects of the therapy. This question was addressed in recent modelling work 
(Murray, Fanning et al. 2009), that considered HSC transduction with a tat-vpr specific anti-
HIV ribozyme (OZ1) employed in a recent phase 2 clinical trial (Mitsuyasu, Merigan et al. 
2009). Under the assumption that 20% of all HSC in the bone marrow are transduced (i.e. 
engraftment percentage P = 20%), and that correspondingly 20% of CD4+ T cells exported 
from the thymus contain the protective gene, the modelling predicted reductions of 0.5 log10 
in viral load for a HAART-naive individual after 1 year (Figure 4 A). Benefits in terms of 
forestalment of onset of AIDS at 8 years post-infection were also estimated (Figure 4 B). 
Slighly less prononunced effects were observed for patients that were concurrently enrolled 
on HAART (Murray, Fanning et al. 2009). Such results are encouraging and indicate that 
relatively modest engraftment percentages could achieve a clinically relevant effect. 
Consequently full bone marrow ablation may be unnecessary. 
3.3 Resistance development under gene-therapy: How does it differ from HAART? 
Systemic antiretroviral therapy bathes each cell in some level of the drugs being used 
depending on the penetration of the individual drugs to that region of the body, their 
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concentration, pharmacokinetics and timing between dosages (Abdel-Rahman and 
Kauffman 2004). The clinical management of the combinations of drugs used in a regimen is 
an important part of successful treatment through suppressing the development of drug 
resistance. Early in the development of antiretroviral drugs there were few agents available 
and by necessity these were applied as monotherapy leading to the failure of these and 
subsequent drugs from the same class. Current HAART regimens involve three drugs from 
at least 2 drug classes to limit the likelihood that mutations in the HIV quasispecies will be 
present prior to the commencement of therapy or will develop subsequently. 
 
 
Fig. 5. Illustration of principles behind selection pressures driving the development of 
resistance with antiretroviral therapy and with gene-therapy. Adapted with permission 
from Applegate et al.(Applegate, Birkett et al. 2010). (A) The horizontal ordinate denotes the 
concentration of antiretroviral drug received, and the vertical ordinate denotes the 
frequency of cells receiving the antiretroviral drug concentration. The selection pressure 
driving resistance in systemic antiretroviral therapy results from bathing each cell in some 
drug concentration. This provides a “continuous spectrum” for selection of HIV escape 
mutants, since many cells will receive suboptimal drug concentrations allowing viral 
replication and the preferential development of drug-resistant strains (as shown by shaded 
region indicated by the arrow). (B) The horizontal ordinate splits the cell population into 
two parts of either having a protective gene or not. The vertical ordinate denotes the 
frequency of cells containing the gene and not containing the gene. The bipartite distribution 
of protected and unprotected results provides a different selection environment whereby 
sufficient wild-type replication takes place in the non-protected population (i.e. no gene), 
thus mitigating the escape of viral mutants. 
Similar concerns exist for the development of resistance to HIV gene therapy (Leonard and 
Schaffer 2006; Applegate, Birkett et al. 2010). The quasispecies nature of HIV and its high 
mutation rate imply the existence of every single mutation to any agent prior to the start of 
therapy. If there is sufficient viral replication under therapy, even for a reasonably short 
period, there is the chance that these singly resistant clones will evolve into variants with 
additional mutations and that are highly resistant to therapy. HIV gene therapy seems to fall 
into the classification of approaches that lend themselves to the development of resistance: 
not all cells will contain the therapy and so there will be considerable viral replication, and 
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this will be even more evident for gene therapy delivered to HSC since it will take some 
time for the protected CD4+ T cells to mature from the HSC and appear in the periphery 
(Applegate, Birkett et al. 2010). However there is a considerable difference between gene 
therapy and a systemic treatment that is not suitably suppressive. 
Unless myeloablation is conducted to eliminate endogenous non-gene containing HSC and 
T cells, it is expected that there will always be a sizeable proportion of HSC and CD4+ T 
cells that do not contain the therapy. Achieving 20% gene transduced HSC without ablation 
may be an upper bound (this remains to be tested). Similar limitations exist for those trials 
that instead transduce peripheral CD4+ T cells. At any time there is an estimated 2% of total 
T cells in peripheral blood and not all T cells are likely to traffic to this compartment. So 
large-scale apheresis of CD4+ T cells from peripheral blood will remove, and be able to 
infuse, only a fraction of their total.  
Hence gene therapy will partition HIV-susceptible cells into a bipartite population: those 
containing the therapy and those that do not. This 0-1 distribution is very different from the 
continuous distribution of drug concentration within cells for an individual receiving 
antiretroviral therapy (Figure 5). In this situation gene therapy is less likely to lead to the 
development of resistance (Applegate, Birkett et al. 2010). However there is a trade-off in 
that it is also less suppressive for the same reason. As cells containing gene therapy become 
more widespread in the body of an infected individual they will exert more pressure on the 
virus and select for resistance (Leonard and Schaffer 2006). For this reason the same general 
principles that apply to antiretroviral therapy are also valid in this context. Gene therapy 
should target multiple viral and cellular mechanisms.  
Mathematical modelling of gene therapy delivered to HSC that targets multiple mechanisms 
with reasonable efficacy and where the resistant virus is also less fit than wild-type 
determined that this therapy will reduce virus and maintain a viable T cell population for 
extended periods without the expansion of resistant virus (Applegate, Birkett et al. 2010). 
However there were important qualifications to the extent of this success. Primarily the gene 
therapy needs to be Class 1 and inhibit infection of cells. Additionally the likelihood of 
resistance to a particular component of the therapy and the fitness cost that incurs will also 
contribute to the speed at which virus overcomes the therapy. 
3.4 Future perspectives: What can we expect from gene-therapy against HIV? 
Gene therapy holds out high promise as an effective therapy against HIV. The definition of 
success of gene-therapy treatment may vary, depending on a variety of circumstances. As 
discussed in Section 2.1, an obvious success would be one similar to that of the Berlin 
Patient whereby an individual would be completely and sustainably cured of HIV and have 
their immune system restored to “normal” levels. It is however important to provide more 
practical goals, as it is not likely that a “cure” will be achieved with all patients, and as such, 
more “modest” goals might be more practical and more realistic. Removing the need for an 
individual to be on HAART would be defined as success, as this can save the individual 
from life-long drug regimens often with considerable side-effects (Yeni 2006). Another 
“successful” outcome might consists in preservation of immune system functionality depite 
the presence of measurable viral loads, as observed during SIV infection in its natural hosts 
(Liovat, Jacquelin et al. 2009; Pandrea, Silvestri et al. 2009). 
As discussed in section 3.2.2 above, predictions from mathematical modelling indicate that 
full ablation of the immune system need not be necessary in order for clinically significant 
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effects to be observed (Murray, Fanning et al. 2009). Assuming HSC engraftment 
percentages of about 20%, it has been predicted that substantial viral control may be 
achieved and CD4+ T cell counts maintained above the critical limit of 200 cells/µL 
(Murray, Fanning et al. 2009). The major challenge to achieving substantial clinical effect 
thus relates to achieving sufficient engraftment percentages. 
Gene therapy will have varying degrees of effectiveness depending on the circumstances of 
the individual. The length of time for which an individual has been infected with HIV is an 
important factor to consider when providing gene therapy treatment. Due to the tropism of 
HIV in an infected individual changing over the duration of infection from CCR5-tropic to 
CXCR4-tropic, any treatment targeting CCR5 would be best used on patients in fairly early-
phase infection (Mosier 2009). For gene-therapy aiming to transduce HSC, it also appears 
reasonable to expect that the therapeutic effects in younger patients will be more 
pronounced due to their greater rates of thymic activity (Pido-Lopez, Imami et al. 2001). 
Futhermore, patients on HAART, patients for whom available antiretroviral therapies have 
been exhausted and patients suffering severe HAART-associated side-effects should also 
benefit, given that gene-therapy provides an alternative layer of protection via cell-mediated 
immunity in addition to antiretroviral therapies (Symonds, Johnstone et al. 2010). 
Finally, as discussed in section 3.2, both HSC and CD4+ T cells represent feasible targets for 
transduction. While CD4+ T cell transduction  may  suffer from limitations due to  a 
restricted T cell receptor repertoire and not protecting other susceptible cell population, it 
will however provide an immediate protected population. Conversely HSC are limited by 
the degree of thymic production and bone marrow engraftment, yet have the potential to 
generate a long-lasting array of HIV protected immune cells. Thus it appears that most 
effective therapies might employ a combination of these two approaches in order to provide 
optimum protection, possibly employing infusions of transduced cells. 
4. Conclusion 
In this chapter we discussed the current biological underpinnings of gene-therapy against 
HIV, as well as predictions from mathematical modelling of the clinical effects achievable 
through gene-therapy. 
We discussed the various biological and clinical aspects relating to HIV gene therapy. An 
indication of the possible effectiveness of gene therapy was provided in terms of the 
naturally occurring mutation, CCR5d32, which provides extremely high levels of resistance 
against HIV infection. Most importantly however, the utilisation of this mutation in a bone 
marrow transplant, ridding an individual of any measurable HIV levels, indicates the 
capability of using gene therapy to functionally “cure” people of HIV. An assessment of the 
target areas of HIV gene therapy was conducted, indicating not only the possibility, but also 
a clear need to target multiple aspects of HIV infection (favourably entry stage), in order to 
prevent the emergence of resistance. The various options for delivery methods were 
discussed, indicating a range of techniques by which to introduce the therapeutic gene. Each 
of these methods exhibit their own advantages and disadvantages, however all are valid 
options in a variety of situations, with lentiviral vectors showing some of the most promise. 
The options for the ideal cell-type to target were discussed, indicating validity of using 
either CD4+ T cells for their immediate effect or HSC for the more sustained and broad 
spectrum protection. However it is also critical to consider the combination of these as an 
option in gene therapy. The aspects and priniciples of apheresis, ablation, and G-CSF-
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induced mobilisation were discussed, indicating their role in treatments. With mobilisation 
being crucial for the efficient transduction of HSC, and ablation of non-tranduced cells 
having the potential to provide a significant proportional increase in the amount of 
protected cells, both are critical when designing treatment regimens. Finally, clinical trials 
whereby HIV gene therapy has been conducted, and the outcomes of these trials were 
summarised, highlighting the high safety levels associated with gene therapuetics. Due to 
the observed high safety in these studies, with the promise of reasonable levels of efficacy 
and a proof of concept (in the Berlin Patient), HIV gene therapies are a very promising area 
of HIV research. 
In the final sections we discussed predictions obtained from mathematical modelling 
regarding the in-vivo effectiveness of gene-therapy. We outlined why HIV virion entry 
inhibition via Class 1 gene-therapy has been shown to be essential in terms of achieving 
clinically meaningful effects. We explained how the selective survival advantage conferred 
to non-infected cells containing the Class 1 protective gene is the key factor contributing to 
the success of Class 1 therapy. We saw that transduction of CD4+ T cells provides an 
immediately protected CD4+ T cell population, but that in-vivo expansion of the protected 
cells may be a slow process and does not result in increased T cell receptor diversity in the 
expanded population. In contrast, transduction of HSC results in higher T cell receptor 
diversity, and in protection of a broader range of cells than solely CD4+ T cells. We also 
discussed the differences in viral resistance development under HAART and under gene-
therapy. While HAART bathes each cell in some drug concentration, resulting in suboptimal 
dosages for many cells and consequent promotion in escape of viral mutants, gene-therapy 
partitions the cell population into protected (contains gene) and unprotected (does not 
contain gene) cell populations. We outlined how this bi-partite distribution promotes the 
expansion of a cell population protected against HIV, while at the same time mitigating 
risks of viral mutation escape as a result of sufficient wild-type viral replication in the non-
protected cell population. Finally, we discussed future perspectives outlining how gene-
therapy promises to achieve sufficient preservation of immune system functionality 
(without HAART-associated toxicity and non-adherence issues) resulting in forestallement 
of AIDS and thereby achieving similar effects as observed during SIV infection in its natural 
hosts. We also outlined how gene-based therapies may be employed in conjunction or 
disjunction with HAART depending on individual patient circumstances and viral tropism 
in the infected individual. 
In conclusion, based on the clinical results and mathematical modeling work to-date, further 
clinical investigation of gene-therapy is more than justified, as gene-therapy holds high 
promise in terms of controlling HIV infection, preserving immune system functionality, and 
prevention of the onset of AIDS. 
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